In this podcast series, Dr. Jenny Seligmann (University of Leeds, UK), Dr. Autumn McRee (University of North Carolina, USA) and Dr. Dominik Modest (Charité University of Medicine, Germany) discuss the different therapeutic options available in colorectal and gastric cancer.
This second episode focuses on recent developments in immunotherapy approaches in metastatic colorectal and gastric cancer – specifically whether immunotherapy should be used alone, in combination with other treatments or with chemotherapy. Data from several clinical trials are discussed such as KEYNOTE-177, CheckMate 142, CheckMate 649, KEYNOTE 062, and NICHE. The experts also consider the appropriate treatment regimens for MSI-high and MSS colorectal and gastric cancer patients and whether CPS is an appropriate biomarker for gastric cancer.
COR2ED Medical Education: Welcome to the "Addressing Anxiety and Pain Around IUD Placement" podcast, where experts in the field, Carolyn Westhoff MD, Michal Yaron...
Do you know how to differentiate between growth hormone deficiency (or GHD) and primary IGF-I deficiency (or growth hormone resistance) and the key challenges...
Do you know how to differentiate between growth hormone deficiency (or GHD) and primary IGF-I deficiency (or growth hormone resistance) and the key challenges...
